Clinical and Clinicopathological Findings of Naturally Occurring Hyperadrenocorticism in Dogs: A Retrospective Study of 17 Cases

다국어 초록 (Multilingual Abstract)

A retrospective study of 17 dogs with hyperadrenocorticism (HAC) was performed to evaluate the clinical
and clinicopathological outcomes in dogs with pituitary-dependent HAC or adrenal gland-dependent HAC. Sixteen dogs
were monitored at day 10, 30 and 90 then every 3 month after first presentation. In each examination, physical
examination and ACTH stimulation test and client questionnaire were performed. In 17 cases, eight dogs were
successfully treated with mitotane therapy (median dose 16.7 mg/kg; range 5.3 to 50 mg/kg, SID); another one dog
showed favorable response, but the clients declined to further treatment before the full control of the disease had been
achieved; four dogs showed poor response to treatment. One dog was euthanized due to septicemia. These results
showed canine HAC can be medically managed successfully without side effects at the doses used in this study.

참고문헌 (Reference)

1 Neiger R, "Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism" 150 : 799-804, 2002

2 Ristic JM, "The use of 17-hydroxyprogesterone in the diagnosis of canine hyperadrenocorticism" 16 : 433-439, 2002

3 Forrester SD, "Retrospective evaluation of urinary tract infection in 42 dogs with hyperadrenocorticism or diabetes mellitus or both" 13 : 557-560, 1999

4 Ruckstuhl NS, "Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane" 63 : 506-512, 2002

5 Kipperman BS, "Pituitary tumor size, neurologic signs, and relation to endocrine test results in dogs with pituitary-dependent hyperadrenocorticism: 43 cases (1980-1990)" 201 : 762-767, 1992

6 Nelson RW, "Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986)" 194 : 1612-1617, 1989

7 Bertoy EH, "One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitarydependent hyperadrenocorticism" 208 : 1268-1273, 1996

8 Kintzer PP, "Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms" 205 : 54-61, 1994

9 Kintzer PP, "Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism" 5 : 182-190, 1991

10 Bertoy EH, "Magnetic resonance imaging of the brain in dogs with recently diagnosed but untreated pituitary-dependent hyperadrenocorticism" 206 : 651-656, 1995

11 Duesberg CA, "Magnetic resonance imaging for diagnosis of pituitary macrotumors in dogs" 206 : 657-662, 1995

12 Ford SL, "Hyperadrenocorticism caused by bilateral adrenocortical neoplasia in dogs: four cases (1983-1988)" 202 : 789-792, 1993

13 Chapman PS, "Evaluation of the basal and postadrenocorticotrophic hormone serum concentrations of 17- hydroxyprogesterone for the diagnosis of hyperadrenocorticism in dogs" 153 : 771-775, 2003

14 Norman EJ, "Dynamic adrenal function testing in eight dogs with hyperadrenocorticism associated with adrenocortical neoplasia" 144 : 551-554, 1999

15 Wood FD, "Diagnostic imaging findings and endocrine test results in dogs with pituitary-dependent hyperadrenocorticism that did or did not have neurologic abnormalities: 157 cases (1989-2005)" 231 : 1081-1085, 2007

16 Behrend EN, "Diagnosis of canine hyperadrenocorticism" 31 : 985-1003, 2001

17 Van Liew CH, "Comparison of results of adrenocorticotropic hormone stimulation and lowdose dexamethasone suppression tests with necropsy findings in dogs: 81 cases (1985-1995)" 211 : 322-325, 1997

18 Feldman EC, "Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs" 200 : 1642-1647, 1992

19 Rijnberk A, "Assessment of two tests for the diagnosis of canine hyperadrenocorticism" 122 : 178-180, 1988

20 Saunders HM, "Adrenal disease. Proceedings" 31-34, 1993

21 Forrester SD, "Absence of urinary tract infection in dogs with experimentally induced hyperadrenocorticism" 74 : 179-182, 2006

22 Barker EN, "A comparison of the survival times of dogs treated with mitotane or trilostane for pituitarydependent hyperadrenocorticism" 19 : 810-815, 2005